Delivery Order SPE2DB22D3501-SPE2DB25FVK61
- Not listed
- The Defense Logistics Agency awarded a $17,009.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of Tecentriq (atezolizumab) 840 mg/14 mL vials on May 19, 2025, with completion targeted for June 10, 2025. This non-set-aside award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, which carries a $999,999,999 ceiling and runs through December 2026. The pharmaceutical distributor is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $8,504.62 on September 19, 2025, for the supply of Tecentriq 840 mg/14 ml vials. This is a firm fixed-price delivery order with an ultimate completion date of October 10, 2025, with performance to be executed at the vendor's facility in Conshohocken, Pennsylvania. The contract represents a non-set-aside award made through open competition, reflecting AmerisourceBergen's demonstrated capability to fulfill...
- The Defense Logistics Agency awarded a $17,009.24 delivery order to AmerisourceBergen Drug Corp for Tecentriq 840 mg/14 ml vials on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order carries no set-aside designation, indicating it was competitively awarded. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters and a major distribution hub for federal pharmaceutical...
- The Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $34,018.40 on September 22, 2025, for the supply of Tecentriq 840 mg/14 ml vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of October 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tecentriq is a specialized oncology pharmaceutical product, reflecting the company's role as a...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on April 24, 2025, for the supply of Tecentriq 840 mg/14 ml vials. The contract is valued at $17,009.24 under a firm fixed-price arrangement with an ultimate completion date of May 15, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $34,018.40 contract is for the supply of 840 mg/14 ml vials of the cancer medication Tecentriq. The delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with DLA Troop Support Medical to provide a wide range of pharmaceutical products and medical supplies in support of military...
- The Defense Logistics Agency awarded a $25,189 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Tecentriq Hybridza 1,875 mg 15 ml pharmaceutical product. This is a non-set-aside competitive award with an ultimate completion date of September 30, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $17,009.24 to AmerisourceBergen Drug Corp for the supply of Tecentriq 840 mg/14 ml vials. This firm fixed-price, competitively awarded contract was issued on August 12, 2025, with an ultimate completion date of September 3, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside acquisition, this delivery order was open to competition among qualified...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of TECENTRIQ 840 MG/14 ML VIAL 14ML. The $8,016.30 firm fixed price contract has a completion date of June 4, 2024. Amerisourcebergen, a major pharmaceutical distributor, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to deliver a wide range of pharmaceutical products and medical supplies...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $16,032.60 Firm Fixed Price delivery order contract is for the supply of 840 mg/14 mL vials of the drug Tecentriq. The contract has an ultimate completion date of August 13, 2024. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025 for...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FVK61Delivery Order
The Defense Logistics Agency awarded a $8,504.62 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Tecentriq (atezolizumab) 840 mg/14 mL vials. This competitively awarded, firm fixed-price contract is scheduled for completion by May 15, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award carries no set-aside designation, reflecting the vendor's capability to compete successfully in open procurement processes for federal pharmaceutical needs. This delivery order represents a child contract under AmerisourceBergen Drug Corp's larger $999.999 billion Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which extends through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems. Tecentriq, an immuno-oncology therapeutic agent, supports the Department of Defense's medical supply requirements across multiple service branches and healthcare facilities. AmerisourceBergen's significant federal contract portfolio with the Defense Logistics Agency demonstrates its position as a critical vendor for military pharmaceutical procurement, delivering a diverse range of medications and medical supplies to support defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.5k | 4/24/25 |